Nested N-terminal megalin fragments induce high-titer autoantibody and attenuated Heymann nephritis.

J Am Soc Nephrol

Department of Pediatrics, University of California, Davis, School of Medicine, 1 Shields Avenue, Davis, CA 95616, USA.

Published: July 2006

It was shown previously that an N-terminal fragment (nM60) that encompasses amino acid residues 1 to 563 of megalin could induce active Heymann nephritis (AHN) as efficiently as the native protein. For delineation of a minimal structure within this fragment that is sufficient to induce AHN, smaller protein fragments that encompass residues 1 to 236 (L6), 1 to 195 (L5), 1 to 156 (L4), and 1 to 120 (L3), representing successive C-terminal truncations within ligand-binding repeats of nM60, were cloned and produced in a baculovirus insect cell expression system. Protein fragments L4, L5, and L6 clearly were glycosylated. All four fragments stimulated proliferation of megalin-sensitized lymph node cells and induced high-titer anti-megalin autoantibodies in Lewis rats. A full-blown disease, as assessed by severity of proteinuria, was observed in rats that were immunized with L6 and L5, whereas animals that were immunized with L4 and L3 developed only mild disease. The proteinuria levels correlated with staining for complement (C3, C5b-9) and IgG1 isotype in glomerular immune deposits. The results suggest that one or more molecular determinants on the region that comprises amino acid residues 157 to 236 contribute to the induction of a full-blown form of AHN. Study of the structure, conformation, and posttranslational modifications of these determinants could provide greater insight into the molecular correlates of immunopathogenesis in this disease model.

Download full-text PDF

Source
http://dx.doi.org/10.1681/ASN.2005101144DOI Listing

Publication Analysis

Top Keywords

heymann nephritis
8
amino acid
8
acid residues
8
protein fragments
8
nested n-terminal
4
n-terminal megalin
4
fragments
4
megalin fragments
4
fragments induce
4
induce high-titer
4

Similar Publications

Background: This study evaluated the efficacy of rituximab (RTX) in primary membranous nephropathy (PMN) patients with incomplete remission and drug dependence after long-term use of calmodulin inhibitors (CNIs). It aims for complete clinical and immunological remission, and cessation of CNI dependence.

Methods: Thirty-six patients were enrolled in the study with two groups: drug-dependent and partial remission or immune non-remission group.

View Article and Find Full Text PDF

Epidemiology of kidney biopsy from regional referral center in Romania: 10-year review.

Rom J Intern Med

December 2024

Department of Nephrology, University of Medicine, and Pharmacy "Iuliu Hatieganu" Cluj-Napoca, 8 Victor Babeș Street, 400012 Cluj-Napoca, Romania.

Purpose: To provide epidemiologic data on kidney biopsy from Romania.

Methods: Retrospective observational study of kidney biopsy records for adult patients from a referral center in the north-western part of Romania, reported for 2014-2023.

Results: 556 biopsies were performed, corresponding to an incidence of 12 biopsies/m person-year with over 50% increase over the last reported year.

View Article and Find Full Text PDF

Background: To compare the efficacy and safety of rituximab (RTX), calcineurin inhibitor (CNI) and cyclophosphamide (CTX) plus glucocorticoids in the treatment of primary membranous nephropathy (PMN).

Methods: Totally 478 biopsy-proven PMN patients in single center were retrospectively included. After 1:1 propensity score matching (PSM), 258 patients were included in RTX, CNI or CTX group (86 patients in each group).

View Article and Find Full Text PDF

Rheumatoid arthritis (RA) is a chronic inflammatory process involving the joints and the cartilage. Early diagnosis and treatment of RA are crucial to prevent further complications like heart failure (HF), cervical subluxation, membranous glomerulonephritis, and parenchymal lung disease. HF is the leading cause of death in various chronic illnesses.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!